{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:57:57Z","timestamp":1770753477760,"version":"3.50.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.kint.2018.03.013","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T19:16:47Z","timestamp":1528917407000},"page":"589-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients"],"prefix":"10.1016","volume":"94","author":[{"given":"Angelo","family":"Karaboyas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hal","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indranil","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Tentori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich K.","family":"Port","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.03.013_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd873","article-title":"Drugs targeting the renin-angiotensin-aldosterone system","volume":"1","author":"Zaman","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2018.03.013_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.03.013_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A\u00a0comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.03.013_bib4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.03.013_bib5","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease","volume":"47","author":"Mancini","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.03.013_bib6","first-page":"1175","article-title":"Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"44","author":"Papademetriou","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.03.013_bib7","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2018.03.013_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ahj.2008.01.031","article-title":"Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis","volume":"155","author":"Balamuthusamy","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2018.03.013_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.03.013_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.ajkd.2016.09.015","article-title":"Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"69","author":"Karaboyas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.03.013_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2215\/CJN.04451206","article-title":"Serum and dialysate potassium concentrations and survival in hemodialysis patients","volume":"2","author":"Kovesdy","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.03.013_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/ndt\/gfp104","article-title":"Sudden death and associated factors in a historical cohort of chronic haemodialysis patients","volume":"24","author":"Genovesi","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1525-1497.1997.07128.x","article-title":"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis","volume":"12","author":"Perazella","year":"1997","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.kint.2018.03.013_bib14","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.03.013_bib15","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"de Jager","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2018.03.013_bib16","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.03.013_bib17","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2013a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.03.013_bib19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.03.013_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.03.013_bib23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2215\/CJN.02010408","article-title":"Associations of kidney function with cardiovascular medication use after myocardial infarction","volume":"3","author":"Winkelmayer","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.03.013_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/j.ajkd.2006.06.006","article-title":"Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients","volume":"48","author":"Roy","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.03.013_bib25","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2018.03.013_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2018.03.013_bib27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.03.013_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2018.03.013_bib29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.03.013_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.03.013_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","article-title":"Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis","volume":"345","author":"Yang","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.kint.2018.03.013_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl\u00a03","key":"10.1016\/j.kint.2018.03.013_bib33","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.03.013_bib34","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/qjmed\/hcn039","article-title":"Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis","volume":"101","author":"Onuigbo","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.kint.2018.03.013_bib36","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin-Angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2018.03.013_bib38","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/ndt\/gfp212","article-title":"Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS","volume":"24","author":"Lopes","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.03.013_bib39","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.03.013_bib40","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.03.013_bib41","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/sim.6404","article-title":"On a preference-based instrumental variable approach in reducing unmeasured confounding-by-indication","volume":"34","author":"Li","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2018.03.013_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA's statement on P values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"suppl 74","key":"10.1016\/j.kint.2018.03.013_bib43","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1046\/j.1523-1755.2000.07413.x","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study","volume":"57","author":"Young","year":"2000","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1016\/j.kint.2018.03.013_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0272-6386(04)01099-6","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology","volume":"44","author":"Pisoni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.03.013_bib45","series-title":"IVEware: Imputation and Variance Estimation Software: User Guide","author":"Raghunathan","year":"2002"},{"key":"10.1016\/j.kint.2018.03.013_bib46","series-title":"Statistical Analysis With Missing Data","author":"Little","year":"1987"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818302539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818302539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:51:06Z","timestamp":1758761466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818302539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0085253818302539"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.03.013","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}